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Background
Allergen-specific immunotherapy (SIT) is the only specific,
disease-modifying treatment for allergy and may have
long-lasting effects. It is given traditionally in the form of
multiple subcutaneous injections which makes the treat-
ment inconvenient. Furthermore, systemic allergen-
administration may cause severe side effects. Therefor the
development of alternative routes for SIT has been a long-
sought goal. The aim of this study was to investigate if epi-
cutaneous application of recombinant birch pollen aller-
gen Bet v 1 (i.e., patch vaccination) can induce systemic
allergen-specific IgG responses with protective activity.
Methods
Groups of outbred female Dunkin Hartley guinea pigs (GP)
(10 animals per group) were immunized subcutaneously
with aluminium hydroxide-adsorbed rBet v 1 (5 µg), alumi-
nium hydroxide alone (negative control) or by patch deliv-
ery system (PDS) using two doses of rBet v 1 (30 µg or 100
µg per patch) on days 1, 15, 28 and 43. ELISA experiments
were performed to measure the development of IgG speci-
fic for Bet v 1, Bet v 1-related pollen and food allergens
(i.e., Aln g 1, Cor a 1, Mal d 1) and for unfolded Bet v 1
fragments. Furthermore, guinea pig antibodies were tested
in IgE ELISA inhibition experiments with allergic patients’
sera to study whether allergen-specific IgG can block aller-
gic patients allergen-specific IgE binding.
Results
Already after 42 days and three s. c. injections of alumi-
nium hydroxide-adsorbed rBet v 1 or three patch test vac-
cinations with the high dose PDS in combination with LT,
a relevant induction of allergen-specific IgG was observed
in more than 20% of the outbred animals. More impor-
tantly, these antisera inhibited allergic patients’ (n=5) IgE
binding to Bet v 1. Interestingly, we noted that only vacci-
nation with aluminium hydroxide-adsorbed rBet v 1
induced IgG antibodies against sequential epitopes and
cross-reactive IgG antibodies whereas patch vaccination
seemed to induce primarily Bet v 1-specific IgG directed
against conformational epitopes.
Conclusion
Our results suggest that patch vaccination with recombi-
nant Bet v 1 may be a promising strategy for SIT against
birch pollen allergy. This study was supported by grant
F4605 of the Austrian Science Fund and a research grant
from Biomay AG, Vienna, Austria.
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